BRISTOL-MYERS SQUIBB was granted conditional approval by Health Canada for the treatment of previously untreated adults with unresectable or metastatic melanoma using Opdivo and Yervoy. The first-ever combination of two immuno-oncology agents has the potential to increase progression-free survival in certain patients. Health Canada also issued a Notice of Compliance with conditions for the OPDIVO...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
